LAVA Therapeutics (LVTX) Competitors

ADC Therapeutics (NYSE:ADCT) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Which has preferable earnings & valuation, ADCT or LVTX?

LAVA Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$70.84M	2.74	-$240.05M	-$1.45	-1.35
LAVA Therapeutics	$4.99M	6.96	-$41.97M	-$1.04	-1.27

Does the media favor ADCT or LVTX?

In the previous week, ADC Therapeutics had 6 more articles in the media than LAVA Therapeutics. MarketBeat recorded 13 mentions for ADC Therapeutics and 7 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 0.76 beat ADC Therapeutics' score of 0.48 indicating that LAVA Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LAVA Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in ADCT or LVTX?

ADC Therapeutics received 38 more outperform votes than LAVA Therapeutics when rated by MarketBeat users. Likewise, 69.23% of users gave ADC Therapeutics an outperform vote while only 64.10% of users gave LAVA Therapeutics an outperform vote.

Company	Underperform	Outperform
ADC Therapeutics	Outperform Votes 63 69.23%	Underperform Votes 28 30.77%
LAVA Therapeutics	Outperform Votes 25 64.10%	Underperform Votes 14 35.90%

Is ADCT or LVTX more profitable?

LAVA Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. ADC Therapeutics' return on equity of 0.00% beat LAVA Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-300.00%	N/A	-61.33%
LAVA Therapeutics	N/A	-62.22%	-29.37%

Do institutionals and insiders believe in ADCT or LVTX?

41.1% of ADC Therapeutics shares are owned by institutional investors. 4.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 0.8% of LAVA Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer ADCT or LVTX?

ADC Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 296.42%. LAVA Therapeutics has a consensus price target of $3.17, indicating a potential upside of 139.90%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe ADC Therapeutics is more favorable than LAVA Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
LAVA Therapeutics	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has more risk and volatility, ADCT or LVTX?

ADC Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.

Summary

ADC Therapeutics beats LAVA Therapeutics on 12 of the 18 factors compared between the two stocks.